Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Soon after the discovery of Kaposi sarcoma (KS)-associated herpesvirus (KSHV), it was appreciated that this virus was associated with most cases of multicentric Castleman disease (MCD) arising in patients infected with human immunodeficiency virus. It has subsequently been recognized that KSHV-MCD is a distinct entity from other forms of MCD. Like MCD that is unrelated to KSHV, the clinical presentation of KSHV-MCD is dominated by systemic inflammatory symptoms including fevers, cachexia, and laboratory abnormalities including cytopenias, hypoalbuminemia, hyponatremia, and elevated C-reactive protein. Pathologically KSHV-MCD is characterized by polyclonal, IgM-lambda restricted plasmacytoid cells in the intrafollicular areas of affected lymph nodes. A portion of these cells are infected with KSHV and a sizable subset of these cells express KSHV lytic genes including a viral homolog of interleukin-6 (vIL-6). Patients with KSHV-MCD generally have elevated KSHV viral loads in their peripheral blood. Production of vIL-6 and induction of human (h) IL-6 both contribute to symptoms, perhaps in combination with overproduction of IL-10 and other cytokines. Until recently, the prognosis of patients with KSHV-MCD was poor. Recent therapeutic advances targeting KSHV-infected B cells with the anti-CD20 monoclonal antibody rituximab and utilizing KSHV enzymes to target KSHV-infected cells have substantially improved patient outcomes. Recently another KSHV-associated condition, the KSHV inflammatory cytokine syndrome (KICS) has been described. Its clinical manifestations resemble those of KSHV-MCD but lymphadenopathy is not prominent and the pathologic nodal changes of KSHV-MCD are absent. Patients with KICS exhibit elevated KSHV viral loads and elevation of vIL-6, homolog of human interleukin-6 and IL-10 comparable to those seen in KSHV-MCD; the cellular origin of these is a matter of investigation. KICS may contribute to the inflammatory symptoms seen in some patients with severe KS or primary effusion lymphoma. Additional research is needed to better define the clinical spectrum of KICS and its relationship to KSHV-MCD. In additional, research is needed to better understand the pathogenesis and epidemiology of both KICS and KSHV-MCD, as well as the optimal therapy for both of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,654 · cited 1×
“…as the causative agent of a several human illnesses, including KS, primary effusion lymphoma (PEL), and, in the setting of human immunodeficiency virus (HIV) infection, almost all cases of multicentric Castleman disease (MCD; Chang et al., 1994; Cesarman et al., 1995; Soulier et al., 1995).”
BackgroundCesarman, E., Chang, Y., Moore, P. S., Said, J. W., & Knowles, D. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321802 · Cited by 2,818 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialSoulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,157 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 2×
“…to signal by forming a tetrameric complex with the IL-6 receptor superfamily gp130 component, which is widely expressed in human tissues, without requiring binding to the classical gp80 IL-6 receptor (Heinrich et al., 1998; Boulanger et al., 2004; Meads and Medveczky, 2004; Hu and Nicholas, 2006).”
BackgroundMolecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 904 · cited 3×
“Their sequence homology is approximately 25% (Moore et al., 1996; Neipel et al., 1997). vIL-6 has a signaling potency 100- to 1000-fold lower that that seen with hIL-6 in in vitro models (Aoki et al., 2000).”
BackgroundNorthfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649 · cited 1×
“Liposomal doxorubicin has a high affinity for the pathogenic spindle cell in KS lesions, and, when available, is currently the standard of care for first line therapy of KS (Northfelt et al., 1998; Cianfrocca et al., 2010).”
BackgroundKinetics of Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression
Sun, R., Lin, S.-F., Staskus, K., Gradoville, L., Grogan, E., Haase, A., & Miller, G. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2232-2242.1999 · Cited by 404 · cited 1×
“Like other herpesviruses, KSHV infection can exhibits both latent and lytic phases, distinguished by their viral gene expression patterns (Moore and Chang, 1998; Staskus et al., 1999; Sun et al., 1999).”
BackgroundKSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine
Ganem, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40567 · Cited by 385 · cited 1×
“The KSHV genome is notable for its molecular piracy of cellular genes (Moore et al., 1996; Ganem, 2010).”
BackgroundDu, M.-Q. (2001) · Blood · doi:10.1182/blood.v97.7.2130 · Cited by 382 · cited 2×
“…of KSHV–MCD is made pathologically by a lymph node biopsy demonstrating hypocellular germinal centers with a vascularized core and by a proliferation of polyclonal, IgM λ-restricted plasmacytoid cells in the interfollicular area (Oksenhendler et al., 1996; Du et al., 2001; Chadburn et al., 2008).”
BackgroundKaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Gene Expression as Revealed by DNA Arrays
Jenner, R. G., Albà, M. M., Boshoff, C., & Kellam, P. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.891-902.2001 · Cited by 379 · cited 2×
“5/vIRF2; a viral homolog of human interleukin-6 (hIL-6) called viral IL-6 (vIL-6; encoded by ORF K2); and a constitutively active G-protein coupled receptor (GPCR) with pro-angiogenic and immunomodulatory functions encoded by ORF74 (Aoki et al., 2000; Jenner et al., 2001; Yarchoan, 2006).”
Background
Cited by
Kaposi sarcoma herpesvirus-associated cancers and related diseases
Goncalves, P. H., Ziegelbauer, J., Uldrick, T. S., & Yarchoan, R. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000330 · Cited by 174
Self-citationKSHV LANA—The Master Regulator of KSHV Latency
Uppal, T., Banerjee, S., Sun, Z., Verma, S., & Robertson, E. (2014) · Viruses · doi:10.3390/v6124961 · Cited by 165
Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.027 · Cited by 155
Self-citation
Metadata
- Authors
- Polizzotto, M. N., Uldrick, T. S., Hu, D., & Yarchoan, R.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 1572-1572
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2069520743
- Cited by
- 196
- References
- 61
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.